350 related articles for article (PubMed ID: 38528629)
1. Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration.
Li W; Li JY
Transl Neurodegener; 2024 Mar; 13(1):16. PubMed ID: 38528629
[TBL] [Abstract][Full Text] [Related]
2. Interface between tauopathies and synucleinopathies: a tale of two proteins.
Galpern WR; Lang AE
Ann Neurol; 2006 Mar; 59(3):449-58. PubMed ID: 16489609
[TBL] [Abstract][Full Text] [Related]
3. Tau and MAPT genetics in tauopathies and synucleinopathies.
Leveille E; Ross OA; Gan-Or Z
Parkinsonism Relat Disord; 2021 Sep; 90():142-154. PubMed ID: 34593302
[TBL] [Abstract][Full Text] [Related]
4. Associations Between APOE Variants, Tau and α-Synuclein.
Rodriguez-Vieitez E; Nielsen HM
Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
[TBL] [Abstract][Full Text] [Related]
5. Tau seeds occur before earliest Alzheimer's changes and are prevalent across neurodegenerative diseases.
Manca M; Standke HG; Browne DF; Huntley ML; Thomas OR; Orrú CD; Hughson AG; Kim Y; Zhang J; Tatsuoka C; Zhu X; Hiniker A; Coughlin DG; Galasko D; Kraus A
Acta Neuropathol; 2023 Jul; 146(1):31-50. PubMed ID: 37154939
[TBL] [Abstract][Full Text] [Related]
6. [Neuropathology of tauopathies and synucleinopathies, and neuroanatomy of sleep disorders: meeting the challenge].
Hauw JJ; Hausser-Hauw C; Duyckaerts C
Rev Neurol (Paris); 2003 Nov; 159(11 Suppl):6S59-70. PubMed ID: 14646802
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.
Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D
ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812
[TBL] [Abstract][Full Text] [Related]
8. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.
Robinson JL; Lee EB; Xie SX; Rennert L; Suh E; Bredenberg C; Caswell C; Van Deerlin VM; Yan N; Yousef A; Hurtig HI; Siderowf A; Grossman M; McMillan CT; Miller B; Duda JE; Irwin DJ; Wolk D; Elman L; McCluskey L; Chen-Plotkin A; Weintraub D; Arnold SE; Brettschneider J; Lee VM; Trojanowski JQ
Brain; 2018 Jul; 141(7):2181-2193. PubMed ID: 29878075
[TBL] [Abstract][Full Text] [Related]
9. Cellular and pathological heterogeneity of primary tauopathies.
Chung DC; Roemer S; Petrucelli L; Dickson DW
Mol Neurodegener; 2021 Aug; 16(1):57. PubMed ID: 34425874
[TBL] [Abstract][Full Text] [Related]
10. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau.
Williams DR
Intern Med J; 2006 Oct; 36(10):652-60. PubMed ID: 16958643
[TBL] [Abstract][Full Text] [Related]
11. Cell-to-Cell Transmission of Tau and α-Synuclein.
Uemura N; Uemura MT; Luk KC; Lee VM; Trojanowski JQ
Trends Mol Med; 2020 Oct; 26(10):936-952. PubMed ID: 32371172
[TBL] [Abstract][Full Text] [Related]
12. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.
Peng C; Gathagan RJ; Lee VM
Neurobiol Dis; 2018 Jan; 109(Pt B):209-218. PubMed ID: 28751258
[TBL] [Abstract][Full Text] [Related]
13. Secondary Protein Aggregates in Neurodegenerative Diseases: Almost the Rule Rather than the Exception.
Moda F; Ciullini A; Dellarole IL; Lombardo A; Campanella N; Bufano G; Cazzaniga FA; Giaccone G
Front Biosci (Landmark Ed); 2023 Oct; 28(10):255. PubMed ID: 37919089
[TBL] [Abstract][Full Text] [Related]
14. The interaction of α-synuclein and Tau: A molecular conspiracy in neurodegeneration?
Yan X; Uronen RL; Huttunen HJ
Semin Cell Dev Biol; 2020 Mar; 99():55-64. PubMed ID: 29738880
[TBL] [Abstract][Full Text] [Related]
15. Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders.
Lopez-Cuina M; Meissner WG
Rev Neurol (Paris); 2022 May; 178(5):460-471. PubMed ID: 35562199
[TBL] [Abstract][Full Text] [Related]
16. Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein.
Quint WH; Matečko-Burmann I; Schilcher I; Löffler T; Schöll M; Burmann BM; Vogels T
J Alzheimers Dis; 2021; 80(2):813-829. PubMed ID: 33579845
[TBL] [Abstract][Full Text] [Related]
17. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
Goedert M
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
[TBL] [Abstract][Full Text] [Related]
18. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease.
Neumann M; Müller V; Görner K; Kretzschmar HA; Haass C; Kahle PJ
Acta Neuropathol; 2004 Jun; 107(6):489-96. PubMed ID: 14991385
[TBL] [Abstract][Full Text] [Related]
19. Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.
Kaur P; Khera A; Alajangi HK; Sharma A; Jaiswal PK; Singh G; Barnwal RP
Mol Neurobiol; 2023 Mar; 60(3):1690-1720. PubMed ID: 36562884
[TBL] [Abstract][Full Text] [Related]
20. Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration.
Goedert M; Masuda-Suzukake M; Falcon B
Brain; 2017 Feb; 140(2):266-278. PubMed ID: 27658420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
